Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab postprandial lipemia and inflammation study in men with type 2 diabetes
NL-OMON43374Not yet recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of alirocumab in type 2 diabetes mellitus (T2DM), sponsored by Franciscus Gasthuis & Vlietland. Primary endpoint: Effect of alirocumab on postprandial leukocyte activation markers. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
alirocumab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON43374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43374.